Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649186 | 0.96 | CHRM3 (0.80) | CHRM3CHRM1AURKAALDH1A1MEN1 | |
| SCHEMBL13649185 | 0.87 | CHRM3 (0.95) | CHRM3CHRM1 | |
| SCHEMBL4098455 | 0.85 | CHRM3 (1.00) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5525503 | 0.81 | CHRM3 (0.64) | CHRM3CHRM1AURKAMEN1LMNA | |
| SCHEMBL4050432 | 0.80 | CHRM3 (0.70) | CHRM3CHRM1AURKAALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL5525505 | 0.79 | CHRM3 (0.62) | CHRM3CHRM1AURKA | |
| Trifluoroacetic Acid SCHEMBL4098047 | 0.78 | CHRM3 (0.88) | CHRM3CHRM1 | |
| SCHEMBL5530860 | 0.78 | CHRM3 (1.00) | CHRM3CHRM1 | |
| SCHEMBL14435017 | 0.75 | CHRM3 (0.98) | CHRM3CHRM1 | |
| SCHEMBL4093955 | 0.74 | CHRM3 (1.00) | CHRM3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM1 8/4885AURKA 3442/4885 |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM1 7/4885AURKA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.